Standard Current Ratio from 2010 to 2026
| LAB Stock | USD 0.93 -0.04 -4.12% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 4.19418695 | Current Value 4.28 | Quarterly Volatility 1.81477008 |
Macro event markers
Review Standard Biotools financial statements over time to add context on performance and capital structure. Key drivers include Depreciation And Amortization of 1.6 M, Interest Expense of 24.7 K or Total Revenue of 91 M along with ratios such as Price To Sales Ratio of 4.42, Dividend Yield of 0.0 or PTB Ratio of 1.88. This view complements Standard Biotools Valuation and Volatility modules.
Standard | Current Ratio | Build AI portfolio with Standard Stock |
Analyzing Standard Biotools's Current Ratio over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Ratio has evolved provides context for assessing Standard Biotools's current valuation and future prospects.
Latest Standard Biotools' Current Ratio Growth Pattern
Below is the plot of the Current Ratio of Standard Biotools over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. Standard Biotools' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Standard Biotools' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 5.87 X | 10 Years Trend |
|
Current Ratio |
| Timeline |
Standard Current Ratio Regression Statistics
| Arithmetic Mean | 4.07 | |
| Geometric Mean | 3.68 | |
| Coefficient Of Variation | 44.59 | |
| Mean Deviation | 1.36 | |
| Median | 4.19 | |
| Standard Deviation | 1.81 | |
| Sample Variance | 3.29 | |
| Range | 7.2802 | |
| R-Value | -0.35 | |
| Mean Square Error | 3.09 | |
| R-Squared | 0.12 | |
| Significance | 0.17 | |
| Slope | -0.12 | |
| Total Sum of Squares | 52.69 |
Standard Current Ratio History
Stock Overview, Methodology & Data Sources
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people. The stock overview for Standard Biotools summarizes business drivers, financial profile, and market behavior. The company is positioned within Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 0.88, profit margin of -87.77%. Standard Biotools has a market cap of 357.84 M, ROE of -13.13%.
Methodology
Unless otherwise specified, financial data for Standard Biotools is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Standard (USA Stocks:LAB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Standard Biotools may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Standard Stock Analysis
A structured review of Standard Biotools often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Standard Biotools Stock. Outlined below are key reports that provide context for Standard Biotools Stock:Review Standard Biotools Correlation against competitors for Standard Biotools. This adds peer-relative context. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.Analysis related to Standard Biotools should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Earnings Share -0.15 | Revenue Per Share | Quarterly Revenue Growth -0.14 | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than book value, which reflects Standard accounting equity. Standard Biotools' market capitalization is 357.84 M. A P/B ratio of 0.88 suggests Standard Biotools trades near or below book value. Enterprise value stands at 217.59 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Standard Biotools' intrinsic value and market price are different measures derived from different inputs. For Standard Biotools, key inputs include a P/B ratio of 0.88, a profit margin of -87.77%, ROE of -13.13%, and revenue of 85.33 M. By contrast, market price reflects the level where buyers and sellers transact.